Skip to main content

Table 3 Adjusted mean change in hemoglobin levels (g/dL) from baseline to first evaluation period (EOC)

From: Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

Coefficient

Estimate

Standard Error

95% CI of Mean

p-value*

ITT Population (N = 126)

 Baseline Value

− 0.6799

0.18076

[−1.038,−0.321]

0.0003

 Darbepoetin alfa

−0.2878

0.32675

[−0.936,−0.360]

0.3805

 Erythropoietin alfa

0.0000

PP Population (N = 93)

 Baseline Value

−0.7725

0.142555

[−1.056,−0.489]

<.0001

 Darbepoetin alfa

−0.4917

0.253015

[−0.994,−0.011]

0.0551

 Erythropoietin alfa

0.0000

  1. Model: Change in Hb levels = Treatment Group+ Site + Baseline value
  2. *p-value was calculated using ANCOVA (two tailed, α = 0.05)